Provided by Tiger Trade Technology Pte. Ltd.

Connect Biopharma Holdings Ltd.

2.36
+0.08003.51%
Post-market: 2.33-0.0300-1.27%19:30 EDT
Volume:444.95K
Turnover:1.03M
Market Cap:148.59M
PE:-1.98
High:2.37
Open:2.30
Low:2.21
Close:2.28
52wk High:3.82
52wk Low:1.23
Shares:62.96M
Float Shares:21.07M
Volume Ratio:1.04
T/O Rate:2.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1933
EPS(LYR):-1.0000
ROE:-140.51%
ROA:-69.75%
PB:5.53
PE(LYR):-2.36

Loading ...

Connect Biopharma Holdings Ltd expected to post a loss of CNY1.41 a share - Earnings Preview

Reuters
·
Mar 27

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 25

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 23

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 20

Connect Biopharma Director James Huang Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

Connect Biopharma President David Leslie Szekeres files initial beneficial ownership statement

Reuters
·
Mar 17

Connect Biopharma CEO and Director Barry D Quart files initial beneficial ownership statement

Reuters
·
Mar 17

Connect Biopharma SVP of Finance Lisa Peraza files initial beneficial ownership statement

Reuters
·
Mar 17

Connect Biopharma Director Kleanthis Gabriel Xanthopoulos Files Initial Beneficial Ownership Statement

Reuters
·
Mar 17

Connect Biopharma director Karen J. Wilson files initial beneficial ownership statement

Reuters
·
Mar 17

Connect Biopharma files Form 3 initial beneficial ownership statement for Director James A. Schoeneck

Reuters
·
Mar 17

Connect Biopharma Director Jean I Liu Files Initial Beneficial Ownership Statement

Reuters
·
Mar 17

Connect Biopharma publishes corporate presentation on rademikibart IL-4Rα antibody development in asthma and COPD

Reuters
·
Mar 10

Connect Biopharma to present Phase 3 rademikibart atopic dermatitis data at AAD Annual Meeting

Reuters
·
Mar 10

Results From Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to Be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (Aad) Annual Meeting

THOMSON REUTERS
·
Mar 10